AN2 Therapeutics (ANTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 annual meeting or until successors are appointed.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxy holders authorized to vote on other business properly brought before the meeting or any adjournments.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and the auditor ratification proposal.
Nominees for Class I directors are Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AN2 Therapeutics
- Q2 2026 net loss rose to $8.2M as R&D spending increased; cash reserves at $79.9M.ANTX
Q2 2026 - Three phase II programs targeting major unmet needs will deliver key data readouts starting this year.ANTX
Jefferies Global Healthcare Conference 2026 - Boron chemistry platform drives expansion into oncology, PV, and rare diseases with multiple catalysts ahead.ANTX
Stifel 2026 Targeted Oncology Virtual Forum - Q1 2026 net loss narrowed to $10.0M, $85.3M cash, and cash runway projected into 2029.ANTX
Q1 2026 - Boron-based therapies advance in hematology, infectious disease, and oncology with pivotal trials ahead.ANTX
Investor presentation - Director elections, auditor ratification, and executive compensation are key meeting topics.ANTX
Proxy filing - Biopharma seeks up to $300M via flexible offerings to fund R&D, with notable dilution risk.ANTX
Registration filing - Reduced net loss, advanced clinical pipeline, and secured funding to extend runway into 2029.ANTX
Q4 2025 - Epetraborole enters Phase 2 for PV, aiming for durable, selective oral hematocrit control in 2026.ANTX
Status update